International Journal of Linguistics Applied Psychology and Technology
https://ijlapt.strjournals.com/index.php/ijlapt
vol. 02 issue 06 (2025)
ISSN: 3048-4529

Could Coffee Play a Role in Managing Obsessive-Compulsive Disorder? A Theoretical Exploration of Neuropharmacological Pathways

Abdullah Faisal Albukhari
Faculty of Medicine, Rabigh, King Abdulaziz University, Saudi Arabia
Email: Aabdulqaderalbukhari@stu.kau.edu.sa
ORCID: https://orcid.org/0009-0004-1482-4411

Abstract

Background:
Obsessive-compulsive disorder (OCD) is a persistent neuropsychiatric disorder marked by unwanted thoughts and repetitive actions, often leading to considerable distress and functional impairment. Despite the effectiveness of selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT) as primary treatment options, many individuals find only limited relief from their symptoms. Caffeine, a stimulant primarily found in coffee, interacts with multiple neurotransmitter systems that are involved in OCD, including serotonin, dopamine, and glutamate.

Objective:
This narrative review seeks to examine the theoretical neuropharmacological processes through which caffeine might affect OCD symptoms, discussing both its potential advantages and drawbacks.

Methods:
A thorough literature review was performed to compile insights from neuroscience, psychopharmacology, and clinical psychiatry regarding the impact of caffeine on brain function and its significance in the context of OCD pathology.

Results:
Caffeine exhibits intricate effects on neural circuits associated with mood regulation, arousal, and compulsivity that vary depending on dosage. While lower to moderate amounts may improve cognitive flexibility and alleviate fatigue, higher doses tend to correlate with heightened anxiety and restlessness. Observations from case studies and preclinical research suggest a possible bidirectional relationship between caffeine consumption and compulsive behaviors, influenced by genetic factors and individual differences. However, there are currently no randomized controlled trials (RCTs) specifically evaluating caffeine's effects on OCD.

Conclusion:
Despite not being an established treatment for OCD, caffeine's impact on relevant neurochemical pathways merits additional research. There is a need for controlled clinical trials to ascertain whether caffeine could act as a therapeutic supplement or if it poses a modifiable risk factor in managing OCD.

Keywords: *OCD, Caffeine, RCT, CBT.*

1. Introduction

Obsessive-compulsive disorder (OCD) is a long-lasting and incapacitating neuropsychiatric disorder marked by intrusive thoughts (obsessions) and the compulsion to perform repetitive actions or mental tasks (compulsions) that individuals feel

compelled to engage in [1]. The estimated worldwide lifetime prevalence of OCD ranges from approximately 2% to 3%, affecting both children and adults across various cultures [2,3]. According to the World Health Organization, it ranks among the ten most disabling medical conditions globally due to the significant distress and functional limitations it imposes on individuals [4].

OCD notably disrupts social interactions, academic performance, and work-related activities. Individuals suffering from this condition frequently experience difficulties with concentration, withdrawal from social situations, and an increased likelihood of comorbid issues such as anxiety, depression, and suicidal thoughts [5,6]. Despite the existence of evidence-based treatments like selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioral therapy (CBT), many patients remain inadequately treated or resistant to treatment [7,8].

Coffee is a popular beverage that contains caffeine—an agent that stimulates the central nervous system primarily by blocking adenosine receptors in the brain [9]. Caffeine affects crucial neurotransmitters such as dopamine and serotonin, which are both relevant to the neurobiology of OCD [10,11]. While moderate consumption of caffeine can enhance alertness and mood in most people, its psychological impacts can differ greatly based on individual sensitivity and dosage levels [12].

This review poses an important question: Can coffee, through its main active ingredient caffeine, potentially influence OCD symptoms by altering neurochemical pathways linked to the disorder? Although coffee itself is not considered a treatment option, understanding its potential effects on OCD-related neurocircuitry could guide future clinical research.

The aim of this narrative review is to investigate potential mechanistic relationships between caffeine and the biological foundations of OCD. By synthesizing insights from neuroscience, psychopharmacology, and psychiatry, this review seeks to offer a theoretically informed foundation for subsequent hypothesis-driven studies.

2. Overview of Obsessive-Compulsive Disorder (OCD)

Obsessive-compulsive disorder (OCD) is characterized by the occurrence of obsessions—persistent and intrusive thoughts, urges, or images that lead to significant anxiety—and compulsions—repetitive actions or mental processes carried out in response to these obsessions or adhering to strict rules [13]. These symptoms are often time-consuming and can result in considerable distress and disruption in daily activities, frequently affecting personal relationships, academic success, and job performance [14].

2.1 Core Symptoms: Obsessions and Compulsions

Obsessions typically revolve around themes such as fear of contamination, concerns about harm, the need for symmetry, or forbidden thoughts. On the other hand, compulsions may manifest as behaviors like excessive handwashing, checking rituals, counting actions, or engaging in mental practices such as silent prayers or repetitive phrases [15]. Individuals

generally acknowledge that their thoughts and behaviors are excessive or irrational but feel unable to control them.

2.2 Neurobiological Basis of OCD

The underlying mechanisms of OCD involve dysfunction within the cortico-striato-thalamo-cortical (CSTC) circuitry—a neural pathway that governs habit formation, decision-making, and error detection [16]. Dysregulation in several critical neurotransmitter systems has been linked to OCD:

Serotonin (5-HT): Reduced activity in serotonin transmission—especially in the orbitofrontal cortex and basal ganglia—has been regarded as a key factor in the pathophysiology of OCD. The effectiveness of selective serotonin reuptake inhibitors (SSRIs) supports this hypothesis [17].

Dopamine: Irregularities in dopaminergic signaling have been noted among some individuals with OCD, particularly within the striatum. Dopamine may play a role in driving compulsive motor actions and reward-related learning processes [18].

Glutamate: Recent studies indicate increased levels of glutamate in the anterior cingulate cortex and caudate nucleus. Dysregulation of glutamatergic signaling could lead to heightened excitability within CSTC circuits and represents a new area for pharmacological intervention [19,20].

2.3 Conventional Treatments

The primary pharmacological treatments for OCD consist of SSRIs that inhibit serotonin reuptake. High-dose SSRIs like fluoxetine, sertraline, and fluvoxamine are approved for treating OCD and typically require an 8–12 week period to achieve full therapeutic effects [21]. Cognitive behavioral therapy (CBT), especially exposure and response prevention (ERP), is also recognized as an effective first-line treatment option; it can be utilized alone or alongside medication [22]. In cases resistant to standard treatment approaches, combining SSRIs with antipsychotics or glutamate-modulating agents such as memantine and riluzole has shown potential benefits [23].

3. Caffeine and the Brain: Mechanisms of Action

Caffeine is a commonly ingested psychoactive substance present in coffee, tea, and numerous energy-boosting products. Its primary mode of action within the central nervous system (CNS) involves non-selectively blocking adenosine receptors, particularly the A1 and A2A subtypes [24]. Adenosine typically has an inhibitory influence on neural activity, which contributes to feelings of sedation and fatigue. By inhibiting these receptors, caffeine enhances neuronal firing and increases neurotransmitter release, resulting in greater alertness and a diminished perception of effort and fatigue [25].

3.1 Adenosine Receptor Antagonism (A1 and A2A)

A1 receptors are widely found throughout the brain and play a role in inhibiting neurotransmitter release, especially within the hippocampus and cerebral cortex.

Caffeine's antagonistic effect at these locations boosts the release of acetylcholine, norepinephrine, and serotonin, thereby increasing arousal and attentiveness [26].

Conversely, A2A receptors are primarily concentrated in the striatum where they coexist with dopamine D2 receptors; they play a significant role in mood regulation, motor function, and motivation. The antagonism by caffeine at A2A receptors indirectly amplifies dopaminergic signaling, particularly in pathways associated with reward mechanisms and compulsion [27]. This relationship may have theoretical implications for obsessive-compulsive disorder (OCD) pathophysiology due to its connection with altered dopaminergic activity within striatal circuits.

3.2 Modulation of Dopamine and Serotonin

In addition to its effects on adenosine receptors, caffeine also influences dopamine transmission as a secondary effect. Research indicates that caffeine increases the availability of dopamine D2/D3 receptors in the striatum, thereby affecting motivation levels and goal-directed behaviors [28]. Furthermore, caffeine appears to impact serotonin (5-HT) turnover in certain brain regions; however, this effect seems to depend on dosage and can vary among individuals [29].

3.3 Behavioral and Psychological Effects

From a psychological perspective, caffeine is linked to improved alertness, enhanced mood states, increased concentration levels, and quicker cognitive processing—especially among those who are sleep-deprived [30]. Nevertheless, excessive or long-term consumption may correlate with heightened anxiety levels, irritability, insomnia issues, and symptoms resembling panic attacks—particularly among sensitive individuals or those already diagnosed with anxiety disorders [31]. These contradictory effects highlight the intricate relationship between caffeine consumption and mental health while suggesting potential relevance to conditions such as OCD; however, clinical validation remains lacking.

4. The Connection Between Coffee and OCD: Theories and Evidence

While there is no direct clinical proof that caffeine or coffee can effectively treat obsessive-compulsive disorder (OCD), various theoretical frameworks and observational studies indicate that caffeine might affect OCD symptoms—either beneficially or detrimentally—based on dosage, individual neurobiology, and coexisting anxiety disorders.

4.1 Caffeine and Anxiety: Conceptual Links to OCD

Caffeine has been historically linked to heightened arousal, vigilance, and anxiety, especially when consumed in large quantities or by those with increased sensitivity [32]. Given that OCD shares neurobiological characteristics with anxiety disorders—particularly regarding serotonergic imbalances and the overactivity of cortico-striatal pathways—it is conceivable that the stimulating properties of caffeine could worsen obsessive thoughts, restlessness, or compulsive actions in vulnerable individuals [33]. In

fact, some research indicates that caffeine's anxiogenic effects may vary with dosage in those predisposed to anxiety or panic disorders, potentially extending to OCD presentations [34].

Conversely, moderate intake of caffeine has been associated with enhanced mood, motivation, and cognitive flexibility—all of which are often compromised in individuals with OCD [35]. This points to a biphasic relationship where lower doses might alleviate specific cognitive symptoms related to OCD, while higher doses could intensify anxiety-driven compulsions.

4.2 Does Caffeine Alleviate or Exacerbate OCD Symptoms?

Preclinical studies suggest that adenosine A2A receptor antagonists like caffeine may have anti-compulsive properties by restoring equilibrium in cortico-striatal glutamate signaling [36]. Research on animals has demonstrated that blocking adenosine receptors can lead to reductions in stereotypical and compulsive behaviors, indicating a neuropharmacological basis for further exploration into caffeine's impact on such behaviors [37].

Nevertheless, data from human subjects remain limited. A few cross-sectional studies indicate that people with OCD might experience increased anxiety and compulsivity after consuming caffeine; however, these results are inconsistent and complicated by the presence of other psychiatric conditions [38].

4.3 Case Studies and Observational Insights

The case literature presents mixed findings. For instance, a report by Koran et al. details an OCD patient whose intrusive thoughts intensified following high caffeine consumption but improved upon cessation of intake [39]. On the other hand, some anecdotal evidence suggests that caffeine may boost motivation for therapy sessions, reduce fatigue, and aid exposure tasks during cognitive-behavioral therapy (CBT) [40].

These opposing effects could be influenced by genetic factors. Variations in the ADORA2A gene associated with the adenosine A2A receptor have been linked to differences in caffeine sensitivity and risk for anxiety [41]. Additionally, variations in serotonin transporter genes may also play a role in how individuals react to caffeine, providing insight into why responses to it can vary significantly among those with OCD symptoms [42].

5. Controversies and Limitations

Although a theoretical link exists between caffeine and obsessive-compulsive disorder (OCD), several limitations prevent drawing any definitive conclusions. The literature presents inconsistent results, highlighting the intricate pharmacodynamics of caffeine, individual differences in response, and a lack of clinical trials specifically focused on OCD.

5.1 Inter-Individual Variability in Caffeine Response

International Journal of Linguistics Applied Psychology and Technology
https://ijlapt.strjournals.com/index.php/ijlapt
vol. 02 issue 06 (2025)
ISSN: 3048-4529

As illustrated in Figure 1, both genetic variations (e.g., ADORA2A and serotonin transporter genes) and caffeine dosage levels contribute to individual differences in OCD symptom modulation. A major limitation in assessing the impact of caffeine on OCD is the considerable inter-individual variability in both pharmacological responses and psychological sensitivity. Elements such as age, gender, metabolic rate, hormonal levels, psychiatric comorbidities, and particularly genetic variations (e.g., in ADORA2A, CYP1A2, and SLC6A4) significantly affect how people metabolize caffeine and experience its central nervous system effects [43,44]. This variability complicates efforts to generalize findings or recommend standardized caffeine interventions for OCD.



Figure 1 Conceptual model of caffeine's impact on OCD symptoms through individual sensitivity factors.This diagram presents a theoretical framework in which caffeine consumption influences OCD symptoms based on genetic predispositions (e.g., ADORA2A and serotonin transporter genes) and dosage-dependent responses. Moderate caffeine intake may enhance mood and cognition, while higher doses are associated with increased anxiety .and compulsivity

5.2 Dose and Duration-Dependent Effects

The connection between caffeine and mental health outcomes—such as anxiety and compulsive behaviors—appears to be dependent on dosage. Moderate intake (for instance, 100–200 mg/day) has been linked to improved mood and cognitive function; however, higher doses (exceeding 400 mg/day) can lead to anxiety, restlessness, increased heart rate, and potentially exacerbated psychiatric symptoms in susceptible individuals [45]. Additionally, the duration of consumption influences these effects: short-term use may produce different neurochemical changes than prolonged use, which can result in receptor adaptation and tolerance [46].

5.3 Risk of Dependence and Symptom Exacerbation

As a psychoactive stimulant, caffeine can cause physical dependence with excessive or regular use. Withdrawal symptoms—including rebound fatigue, irritability, and heightened obsessive thoughts—have been noted during periods without caffeine consumption; these symptoms may resemble or intensify those associated with OCD, especially among individuals predisposed to compulsive behaviors [47]. This creates a clinical challenge regarding whether caffeine contributes to a cycle of compulsive behavior that reinforces symptoms.

5.4 Lack of Targeted Clinical Trials

The most significant limitation is likely the absence of randomized controlled trials (RCTs) or extensive observational studies that directly evaluate the impact of caffeine or coffee on OCD symptoms. Much of the existing research is indirect—often stemming from studies related to anxiety or general psychiatry—or consists mainly of isolated case reports along with preclinical data. Without meticulously designed studies to establish causal relationships, any conclusions drawn remain speculative [48].

6. Future Directions

In light of the current scarcity of clinical evidence, future investigations into the potential link between caffeine and obsessive-compulsive disorder (OCD) should focus on well-structured randomized controlled trials (RCTs). These studies would yield the most reliable evidence to ascertain whether caffeine has a therapeutic, neutral, or negative impact on OCD symptoms.

A particularly promising avenue for research is examining the dose-response relationship between caffeine intake and symptom severity in individuals diagnosed with OCD. Such research could categorize participants based on their caffeine consumption levels (e.g., low, moderate, high) and monitor changes in obsessive thoughts, compulsive actions, and anxiety over time. This approach would aid in determining whether there is a specific threshold at which caffeine becomes harmful or if lower doses might alleviate symptoms in certain subgroups.

To enhance the reliability and reproducibility of results, future research should utilize standardized and objective assessment tools like the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). This recognized clinical tool facilitates quantitative monitoring of symptom progression and treatment effectiveness across different time intervals. Additionally, incorporating neuroimaging techniques, genetic analysis, and psychometric evaluations may reveal biomarkers that account for individual differences in responses to caffeine among those with OCD.

Moreover, future studies ought to consider confounding factors such as co-existing anxiety or depression disorders, medication usage (e.g., SSRIs or antipsychotics), sleep habits, and general caffeine tolerance—elements that could significantly affect outcomes.

By addressing these important gaps in knowledge, forthcoming research could elucidate whether caffeine has any clinical significance—or poses risks—in treating OCD while contributing to a more comprehensive understanding of its neuropsychiatric implications.

7. Conclusion

This narrative review examined the theoretical link between caffeine, particularly through coffee intake, and obsessive-compulsive disorder (OCD). Although caffeine influences neurochemical pathways associated with OCD, such as serotonin, dopamine, and glutamate, the existing evidence does not sufficiently endorse its application as a treatment option.

The relationship is intricate and varies significantly among individuals. In some instances, low to moderate consumption of caffeine may improve mood, motivation, and cognitive function; however, at higher doses, it could exacerbate anxiety and compulsive behaviors. The absence of direct clinical trials further restricts the ability to establish clear conclusions.

Currently, caffeine should not be regarded as a therapeutic approach for OCD. Nonetheless, its capacity to influence pertinent neurobiological circuits indicates that it might have an indirect role deserving further exploration. Future studies employing controlled designs and standardized tools for symptom assessment are crucial to ascertain whether caffeine serves as a risk factor, a harmless stimulant, or a beneficial adjunct in certain populations affected by OCD.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR®). 5th ed., 2022.
2. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53–63.
3. Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive–compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):327–337.
4. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: WHO; 2008.
5. Torres AR, Prince MJ, Bebbington PE, et al. Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am J Psychiatry. 2006;163(11):1978–1985.
6. Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry. 2013;47(2):121–141.
7. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2004;65(suppl 14):6–10.
8. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850–855.
9. Nehlig A. Is caffeine a cognitive enhancer? J Alzheimers Dis. 2010;20(s1):S85–S94.
10. Du, Z., Jiang, Y., Shen, Y., Zhou, Q., Gong, P., & Zhu, H. (2025). Association Between Coffee Intake and Common Mental Disorders: Insights From Genetic Analysis. *CNS Neuroscience & Therapeutics*, 31. https://doi.org/10.1111/cns.70213.
11. Temple JL, Bernard C, Lipshultz SE, et al. The safety of ingested caffeine: a comprehensive review. Front Psychiatry. 2017;8:80.
12. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol. 2002;40(9):1243–1255.

13. Stein DJ, Costa DLC, Lochner C, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5(1):52.
14. Mataix-Cols D, do Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive–compulsive disorder. Am J Psychiatry. 2005;162(2):228–238.
15. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374(9688):491–499.
16. Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43–51.
17. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37(3):375–391.
18. Denys D, Zohar J, Westenberg HGM. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65(Suppl 14):11–17.
19. Brennan BP, Rauch SL, Jensen JE, Pope HG Jr. A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder. Biol Psychiatry. 2013;73(1):24–31.
20. Pittenger C. Glutamatergic agents for OCD and related disorders. Curr Treat Options Psychiatry. 2015;2(3):271–283.
21. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765.
22. McKay D, Abramowitz JS, Calamari JE, et al. A critical evaluation of obsessive–compulsive disorder subtypes: symptoms versus mechanisms. Clin Psychol Rev. 2004;24(3):283–313.
23. Rodriguez CI, Bender J, Jr., Marcus SM, et al. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J Clin Psychiatry. 2010;71(9):1247–1249.
24. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83–133.
25. Ribeiro JA, Sebastião AM. Caffeine and adenosine. J Alzheimers Dis. 2010;20(s1):S3–S15.
26. Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem. 2008;105(4):1067–1079.
27. Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol. 2005;16(2):63–77.
28. Volkow ND, Wang GJ, Logan J, et al. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry. 2015;5(4):e549.
29. Nikodijevic O, Jacobson KA, Daly JW. Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav. 1993;44(1):199–216.
30. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl). 2005;179(4):813–825.
31. Mitra, S., Miranda, V., McMillan, C., Dykes, D., Mucha, M., Marth, T., Poe, B., Basu, D., & Bult-Ito, A. (2020). Trait specific modulatory effects of caffeine exposure on compulsive-like behaviors in a spontaneous mouse model of obsessive-compulsive disorder. *Behavioural Pharmacology*, 31, 622 - 632. https://doi.org/10.1097/FBP.0000000000000570.
32. Winston AP, Hardwick E, Jaberi N. Neuropsychiatric effects of caffeine. Adv Psychiatr Treat. 2005;11(6):432–439.
33. Calamaro CJ, Mason TB, Ratcliffe SJ. Adolescents living the 24/7 lifestyle: effects of caffeine and technology on sleep duration and daytime functioning. Pediatrics. 2009;123(6):e1005–e1010.
34. Lara DR. Caffeine, mental health, and psychiatric disorders. J Alzheimers Dis. 2010;20(s1):S239–S248.
35. Brunyé TT, Mahoney CR, Lieberman HR, Taylor HA. Caffeine modulates attention network function. Brain Cogn. 2010;72(2):181–188.
36. El Yacoubi M, Ledent C, Parmentier M, et al. Adenosine A2A receptor antagonists are potential therapeutic agents for psychiatric diseases. J Neurochem. 2001;77(3):871–879.
37. Simola N, Morelli M, Frazzitta G, et al. Adenosine A2A antagonists and compulsive behaviors: experimental evidence and therapeutic potential. Neurosci Biobehav Rev. 2010;34(3):431–444.

38. Temple JL, Ziegler AM. Gender differences in subjective and physiological responses to caffeine and the role of steroid hormones. J Caffeine Res. 2011;1(1):41–48.
39. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(Suppl):5–53.
40. Bitter EA. Critical Care Handbook of the Massachusetts General Hospital. 7th ed. McGraw-Hill Education; 2023.
41. Alsene K, Deckert J, Sand P, de Wit H. Association between A2A receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology. 2003;28(9):1694–1702.
42. Childs E, Hohoff C, Deckert J, Xu K, Badner J, de Wit H. Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology. 2008;33(12):2791–2800.
43. Yang A, Palmer AA, de Wit H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl). 2010;211(3):245–257.
44. Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Curr Opin Lipidol. 2007;18(1):13–19.
45. Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam. 2003;20(1):1–30.
46. Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 2018;70(2):384–411.
47. Juliano LM, Griffiths RR. A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology (Berl). 2004;176(1):1–29.
48. Pino RM. Clinical Anesthesia Procedures of the Massachusetts General Hospital. 10th ed. Wolters Kluwer; 2022.